JP7781762B2 - エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 - Google Patents
エンシフェントリンおよびグリコピロレートを含む液体医薬組成物Info
- Publication number
- JP7781762B2 JP7781762B2 JP2022551825A JP2022551825A JP7781762B2 JP 7781762 B2 JP7781762 B2 JP 7781762B2 JP 2022551825 A JP2022551825 A JP 2022551825A JP 2022551825 A JP2022551825 A JP 2022551825A JP 7781762 B2 JP7781762 B2 JP 7781762B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- ensifentrine
- glycopyrrolate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025203938A JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2002786.8 | 2020-02-27 | ||
| GBGB2002786.8A GB202002786D0 (en) | 2020-02-27 | 2020-02-27 | Liquid pharmaceutical composition |
| PCT/GB2021/050496 WO2021171034A1 (en) | 2020-02-27 | 2021-02-26 | Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203938A Division JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516630A JP2023516630A (ja) | 2023-04-20 |
| JP2023516630A5 JP2023516630A5 (OSRAM) | 2024-02-29 |
| JP7781762B2 true JP7781762B2 (ja) | 2025-12-08 |
Family
ID=70278709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551825A Active JP7781762B2 (ja) | 2020-02-27 | 2021-02-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
| JP2025203938A Pending JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203938A Pending JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20230112220A1 (OSRAM) |
| EP (2) | EP4306129A3 (OSRAM) |
| JP (2) | JP7781762B2 (OSRAM) |
| KR (1) | KR20220149669A (OSRAM) |
| CN (1) | CN115279343A (OSRAM) |
| AU (1) | AU2021227456A1 (OSRAM) |
| BR (1) | BR112022016015A2 (OSRAM) |
| CA (1) | CA3166952A1 (OSRAM) |
| DK (1) | DK4110292T3 (OSRAM) |
| ES (1) | ES2970571T3 (OSRAM) |
| FI (1) | FI4110292T3 (OSRAM) |
| GB (1) | GB202002786D0 (OSRAM) |
| HR (1) | HRP20240288T1 (OSRAM) |
| HU (1) | HUE065531T2 (OSRAM) |
| IL (1) | IL295442A (OSRAM) |
| LT (1) | LT4110292T (OSRAM) |
| MX (1) | MX2022010014A (OSRAM) |
| PH (1) | PH12022552278A1 (OSRAM) |
| PL (1) | PL4110292T3 (OSRAM) |
| PT (1) | PT4110292T (OSRAM) |
| RS (1) | RS65330B1 (OSRAM) |
| SI (1) | SI4110292T1 (OSRAM) |
| SM (1) | SMT202400076T1 (OSRAM) |
| WO (1) | WO2021171034A1 (OSRAM) |
| ZA (1) | ZA202208763B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| EP4609864A4 (en) * | 2022-10-28 | 2026-02-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| CN121620356A (zh) | 2023-06-26 | 2026-03-06 | 维罗纳制药公司 | 包含恩塞芬汀的颗粒组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016510804A (ja) | 2013-03-15 | 2016-04-11 | ヴェローナ ファーマ ピーエルシー | 複合製剤 |
| JP2017528479A (ja) | 2014-09-15 | 2017-09-28 | ヴェローナ ファーマ ピーエルシー | Ｒｐｌ５５４を含む液体吸入製剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2368413C (en) | 1999-03-31 | 2008-07-29 | Verona Pharma Plc | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| NZ587561A (en) * | 2008-02-26 | 2012-10-26 | Elevation Pharmaceuticals Inc | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist) |
-
2020
- 2020-02-27 GB GBGB2002786.8A patent/GB202002786D0/en not_active Ceased
-
2021
- 2021-02-26 DK DK21709782.3T patent/DK4110292T3/da active
- 2021-02-26 PH PH1/2022/552278A patent/PH12022552278A1/en unknown
- 2021-02-26 SM SM20240076T patent/SMT202400076T1/it unknown
- 2021-02-26 MX MX2022010014A patent/MX2022010014A/es unknown
- 2021-02-26 EP EP23213674.7A patent/EP4306129A3/en active Pending
- 2021-02-26 BR BR112022016015A patent/BR112022016015A2/pt unknown
- 2021-02-26 FI FIEP21709782.3T patent/FI4110292T3/fi active
- 2021-02-26 JP JP2022551825A patent/JP7781762B2/ja active Active
- 2021-02-26 IL IL295442A patent/IL295442A/en unknown
- 2021-02-26 CA CA3166952A patent/CA3166952A1/en active Pending
- 2021-02-26 HU HUE21709782A patent/HUE065531T2/hu unknown
- 2021-02-26 PL PL21709782.3T patent/PL4110292T3/pl unknown
- 2021-02-26 EP EP21709782.3A patent/EP4110292B1/en active Active
- 2021-02-26 ES ES21709782T patent/ES2970571T3/es active Active
- 2021-02-26 KR KR1020227029927A patent/KR20220149669A/ko active Pending
- 2021-02-26 HR HRP20240288TT patent/HRP20240288T1/hr unknown
- 2021-02-26 LT LTEPPCT/GB2021/050496T patent/LT4110292T/lt unknown
- 2021-02-26 AU AU2021227456A patent/AU2021227456A1/en active Pending
- 2021-02-26 SI SI202130101T patent/SI4110292T1/sl unknown
- 2021-02-26 PT PT217097823T patent/PT4110292T/pt unknown
- 2021-02-26 US US17/904,816 patent/US20230112220A1/en active Pending
- 2021-02-26 RS RS20240350A patent/RS65330B1/sr unknown
- 2021-02-26 CN CN202180016396.7A patent/CN115279343A/zh active Pending
- 2021-02-26 WO PCT/GB2021/050496 patent/WO2021171034A1/en not_active Ceased
-
2022
- 2022-08-04 ZA ZA2022/08763A patent/ZA202208763B/en unknown
-
2025
- 2025-11-26 JP JP2025203938A patent/JP2026035711A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016510804A (ja) | 2013-03-15 | 2016-04-11 | ヴェローナ ファーマ ピーエルシー | 複合製剤 |
| JP2017528479A (ja) | 2014-09-15 | 2017-09-28 | ヴェローナ ファーマ ピーエルシー | Ｒｐｌ５５４を含む液体吸入製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2970571T3 (es) | 2024-05-29 |
| JP2026035711A (ja) | 2026-03-04 |
| CN115279343A (zh) | 2022-11-01 |
| SI4110292T1 (sl) | 2024-03-29 |
| FI4110292T3 (fi) | 2024-03-01 |
| LT4110292T (lt) | 2024-02-12 |
| GB202002786D0 (en) | 2020-04-15 |
| KR20220149669A (ko) | 2022-11-08 |
| EP4110292A1 (en) | 2023-01-04 |
| MX2022010014A (es) | 2022-10-18 |
| SMT202400076T1 (it) | 2024-03-13 |
| EP4110292B1 (en) | 2024-01-10 |
| IL295442A (en) | 2022-10-01 |
| AU2021227456A1 (en) | 2022-09-08 |
| EP4306129A3 (en) | 2024-04-17 |
| DK4110292T3 (da) | 2024-02-19 |
| BR112022016015A2 (pt) | 2022-10-11 |
| RS65330B1 (sr) | 2024-04-30 |
| PH12022552278A1 (en) | 2024-03-04 |
| HUE065531T2 (hu) | 2024-05-28 |
| JP2023516630A (ja) | 2023-04-20 |
| WO2021171034A1 (en) | 2021-09-02 |
| PL4110292T3 (pl) | 2024-05-20 |
| US20230112220A1 (en) | 2023-04-13 |
| CA3166952A1 (en) | 2021-09-02 |
| ZA202208763B (en) | 2024-01-31 |
| HRP20240288T1 (hr) | 2024-05-24 |
| PT4110292T (pt) | 2024-01-31 |
| EP4306129A2 (en) | 2024-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026035711A (ja) | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 | |
| AU2020203081B2 (en) | Liquid inhalation formulation comprising RPL554 | |
| JP6919093B2 (ja) | 配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも１種の乾燥粉末を含む組成物 | |
| AU2020328223A1 (en) | Pharmaeutical composition comprising ensifentrine | |
| JP2025528141A (ja) | 液体医薬組成物 | |
| JP6415536B2 (ja) | ブデソニドおよびフォルモテロールを含む医薬組成物 | |
| CN103347518A (zh) | 含有抗毒蕈碱药物的无推进剂液体制剂 | |
| WO2020141472A1 (en) | Nebulization composition comprising tiotropium and indacaterol | |
| RU2831388C1 (ru) | Жидкая фармацевтическая композиция, содержащая энсифентрин и гликопирролат | |
| HK40097440A (en) | Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate | |
| HK40077584A (en) | Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate | |
| HK40077584B (en) | Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate | |
| US20240108617A1 (en) | An inhalable dry powder composition for pulmonary diseases | |
| KR102449403B1 (ko) | 부데소니드 및 포르모테롤을 함유하는 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221020 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20221020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250610 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250910 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251028 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251126 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7781762 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |